The victory won by Natco will prompt other companies to innovate pricing schemes that will pave the way for other drugs becoming cheaper, feels Shamnad Basheer, a law professor who has written extensively about the case. Once Natco launches a generic version of Nexavar at Rs 8,800 per month, a fraction of the Rs 2.8 lakh that it costs now. around 9,000 patients suffering from kidney and liver cancer in India will benefit from it, Professor Basheer, who is in the faculty of the West Bengal National University of Juridical Sciences, told The Indian Express over the phone.